Compare MSBI & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSBI | ARMP |
|---|---|---|
| Founded | 1881 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 456.2M | 383.7M |
| IPO Year | N/A | 1996 |
| Metric | MSBI | ARMP |
|---|---|---|
| Price | $21.96 | $8.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $22.83 | $15.00 |
| AVG Volume (30 Days) | ★ 99.1K | 40.8K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 6.09% | N/A |
| EPS Growth | N/A | ★ 53.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.41 | N/A |
| Revenue Next Year | $2.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.24 | $0.90 |
| 52 Week High | $24.57 | $13.75 |
| Indicator | MSBI | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 53.12 | 42.76 |
| Support Level | $20.47 | $5.14 |
| Resistance Level | $22.29 | $12.11 |
| Average True Range (ATR) | 0.57 | 0.90 |
| MACD | 0.10 | -0.44 |
| Stochastic Oscillator | 81.64 | 24.72 |
Midland States Bancorp Inc is a diversified financial holding company. The company provides a full range of commercial and consumer banking products and services, business equipment financing, merchant credit card services, trust and investment management, and insurance and financial planning services. The Banking segment, which generates the majority of the revenue, provides financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage, and other consumer loan products; commercial equipment financing, etc. The Wealth Management segment consists of trust and fiduciary services, brokerage, and retirement planning services. The Corporate segment includes the holding company's financing and investment activities, administrative expenses.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.